Systematic review and meta-analysis of health state utility for global patients with hemophilia
- VernacularTitle:全球血友病患者健康效用值的系统综述与Meta分析
- Author:
Junchao FENG
1
,
2
,
3
;
Shunping LI
1
,
2
,
3
;
Yunhai FANG
4
;
Zhao SHI
1
,
2
Author Information
1. Center for Health Management and Policy Research，School of Public Health，Cheeloo College of Medicine，Shandong University，Jinan 250012，China
2. NHC Key Lab of Health Economics and Policy Research （Shandong University），Jinan 250012，China
3. Center for Health Preference Research，Shandong University，Jinan 250012，China
4. Shandong Haemophilia Treatment Center，Shandong Blood Center，Jinan 250014，China
- Publication Type:Journal Article
- Keywords:
rare diseases;
hemophilia;
health state utility
- From:
China Pharmacy
2023;34(24):3012-3019
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To systematically sort out and evaluate the health state utility of hemophiliac patients， and to provide reliable parameters for conducting pharmacoeconomic evaluation and health technology assessment. METHODS Retrieved from CNKI， Wanfang data， VIP， CBM， PubMed， Embase， the Cochrane Library， Scopus and Web of Science databases， relevant literature about the measurement of health state utility in hemophiliac patients was collected from the inception to February 2023. After screening literature， extracting data and evaluating the quality of literature， meta-analysis was performed for health state utility with Stata 15.1 software. RESULTS Thirty-eight papers were finally included， with the highest and lowest health utility values of 0.90 and 0.46， respectively. Those studies mostly adopted the EuroQol Five Dimensions Questionnaire （EQ-5D） （73.7%）. Results of meta-analysis showed that health state utility of global hemophiliac patients was 0.69，95% confidence interval was 0.65- 0.74； those of patients with mild， moderate and severe hemophilia were 0.79， 0.70， and 0.64， respectively； health state utility for patients with inhibitors （0.64） was lower than that of patients without inhibitors （0.69）； health state utility for the Chinese patient population was 0.55， which was higher than that of Iranian patients （0.46）， but lower than those of other developed countries. CONCLUSIONS There is some heterogeneity in the results of the studies across countries/regions， with higher health state utility in developed countries than in developing countries. As the severity of hemophilia increases， the trend of decreasing health state utility is obvious.
